VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline
News Dec 29, 2008
VIA Pharmaceuticals, Inc. has announced exclusive, worldwide licensing agreements with Roche for two sets of compounds.
The first was for Roche's thyroid hormone receptor (THR) beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The second was for multiple compounds from Roche's preclinical diacylglycerol acyl transferase 1 (DGAT1) metabolic disorders program.
Under the terms of the agreements, VIA will assume control of all development and commercialization of the compounds, and will own exclusive worldwide rights for all potential indications. The agreements provide for milestone payments for development and royalties upon commercialization.
"We are pleased to significantly expand our pipeline of promising compounds with the in-licensing of these two programs. The THR beta agonist candidate and the DGAT1 program are natural fits for VIA, and build on the company's cardiovascular inflammation programs," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals.
"We believe that these compounds address other critical underlying causes of cardiovascular disease: hyperlipidemias and metabolic disorders including diabetes. In addition, Dr. Rebecca Taub, our senior vice president of research and development, has significant experience in heading up development programs in metabolic diseases, and previously oversaw both the THR beta agonist and DGAT1 programs at Roche. We look forward to moving the THR beta agonist into clinical development," Cohen said.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Plant Peptide Gives Relief From Salty StressNews
Researchers have discovered a hormone-like peptide in plants that helps increase their tolerance to excessive salt. They found several genes that can increase salinity tolerance, the most effective being a small gene that codes for the peptide AT13READ MORE